SDG 17
PARTNERSHIP
FOR THE GOALS







17 PARTNERSHIPS FOR THE GOALS













LIAQUAT UNIVERSITY
OF MEDICAL & HEALTH SCIENCES
JAMSHORO

LUMHS Contribution to National and Regional SDG Policy Development

Yes. Liaquat University of Medical & Health Sciences (LUMHS) has direct involvement in and contributes expertise to national and regional public-sector and non-governmental initiatives relevant to the Sustainable Development Goals (SDGs), particularly SDG 3 (Good Health and Well-being), SDG 4 (Quality Education), SDG 5 (Gender Equality), SDG 6 (Clean Water and Sanitation), SDG 10 (Reduced Inequalities), and SDG 17 (Partnerships for the Goals). Through its academic, clinical, research, public-health and community-engagement functions, LUMHS faculty and experts contribute to identifying health and social challenges, generating evidence, providing technical input, participating in consultations and professional forums, and supporting the development and implementation of policies, strategies and interventions. LUMHS also contributes to disease surveillance, antimicrobial-resistance monitoring, health needs assessment, community health programmes and evaluation of interventions, providing evidence that can inform government and partner organizations in planning and adapting programmes. Its collaborations with organizations such as WHO and other national and international health partners, together with engagement with government departments and community organizations, provide mechanisms for knowledge sharing, monitoring outcomes and translating academic and clinical expertise into policy and practice. These activities demonstrate LUMHS's role not only in implementing SDG-related programmes but also in evidence generation, policy input, monitoring, reporting and adaptive improvement at regional and national levels.

Hyderabad Cancer Registry (HCR),

Liaquat University of Medical & Health Sciences (LUMHS) has direct involvement and provides evidence-based input relevant to health policy development through its Hyderabad Cancer Registry (HCR) and associated public-health activities. LUMHS, through the Hyderabad Cancer Registry, collects, maintains, analyses, and reports cancer data from across Sindh, including remote and underserved areas. The HCR was established in association with the strengthening of diagnostic services at LUMHS and its extensive outreach programme, which enables cancer cases to be identified and recorded from different districts of the province. The registry collected and analyzed data on **7,169 malignant cases during 2020–2023**, providing population-level evidence on cancer incidence, age, gender and tumor patterns.

The evidence generated by LUMHS helps **identify health problems and challenges**, particularly the burden and distribution of cancer in Sindh. The registry identified breast cancer as the most common malignancy overall and oral cancer as the leading cancer among males, while also highlighting the increasing occurrence of breast and other cancers among younger populations. The report identifies preventable risk factors, including prevalent chewing habits associated with oral cancer, and highlights gaps in early diagnosis, cancer registration and genetic screening.

Importantly, the HCR findings are intended to support **cancer-control prioritization and allocation of limited health resources**. The published report states that the findings should serve as a guideline for estimating the cancer burden and risk in Sindh and Pakistan and may

assist the Sindh government and private sector in prioritizing resources for cancer-control programmes.

LUMHS therefore contributes to the policy cycle by providing **evidence for problem identification, risk assessment, prioritization, monitoring and reporting of health interventions**. Its registry data also provides a basis for identifying emerging trends and gaps that can inform future cancer-prevention, screening, diagnostic and control strategies. The HCR's broad geographical coverage, including multiple districts and remote areas of Sindh, strengthens its value as a regional evidence source for health planning.

Evidence of impact: The *Hyderabad (Sindh, Pakistan) Cancer Registry Report of Four Years (2020–2023)*, published in the *Journal of the College of Physicians and Surgeons Pakistan* in 2025, demonstrates LUMHS's institutional role in generating and disseminating health evidence for cancer-control planning in Sindh.



ORIGINAL ARTICLE OPEN ACCESS

Hyderabad (Sindh, Pakistan) Cancer Registry Report of Four Years (2020-2023)

Shahid Pervez[1], Muhammad Rahil Khan[2], Ikram Din Ujjan[2], Nazia Mumtaz[3], Ejaz Alam[4] and Huma Qureshi[4]

[1]*Department of Pathology and Laboratory Medicine, The Aga Khan University Hospital, Karachi, Pakistan*
[2]*Department of Pathology, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan*
[3]*Department of Pathology, Bilawal Medical College, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan*
[4]*Pakistan Health Research Council, Jinnah Postgraduate Medical Centre, Karachi, Pakistan*

ABSTRACT

Objective: To collect and analyse cancer data of all malignancies from the Hyderabad Cancer Registry (HCR) for the estimation of cancer incidence (2020-2023) in various age groups and genders to identify common malignancies and any risk factors to facilitate cancer control initiative and prioritisation by the government and private sector.

Study Design: Observational study.

Place and Duration of the Study: Hyderabad Cancer Registry (HCR) Secretariat, Liaquat University of Health Sciences (LUMHS), Jamshoro, in collaboration with Karachi Cancer Registry, Health Research Institute, NICH, JPMC, Karachi, Pakistan, from January 2020 to December 2023.

Methodology: Cancer data of HCR collected from across Sindh province were analysed using SPSS. Parameters included age, gender, first contact date, primary site, and ICD coding. Data were cleaned, merged, and analysed. As per the standard guidelines, patients aged 0-14 years were classified as children, 15-19 years as adolescents, and aged 20 years and above as adults. Age-standardised incidence rates (ASIR) were also determined.

Results: During these four years, i.e., from January 2020 to December 2023, a total of 7,169 malignant cases were received. This included 3,310 (46.2%) males and 3,859 (53.8%) females, respectively. Out of a total of 7,169 cases, 6,967 (97.18%) tumours were seen in adults (≥20 years), 104 (1.45%) in adolescents, and 98 (1.37%) in children. In male adults, the oral, prostate, and urinary bladder, while in females, the breast, oral, and ovary constituted the three most common sites. The overall ASIR in males was 188.96 for adults, 2.25 for adolescents, and 2.41 for children. The overall ASIR in females was 236.68 for adults, 2.17 for adolescents, and 1.62 for children.

Conclusion: Both genders combined, breast cancer was the most common malignancy in Sindh. Oral cancer (OC) topped the list in males as the most common cancer, while it was 2nd most common in females after breast. OC, though largely a preventable cancer, has shown an upward trend mostly due to highly prevalent chewing habits, while breast cancer, largely a non- preventable one, not only shows an upward trend but more and more cases are occurring in young and pre-menopausal women. In adolescents and children, the orbital, oral, brain, colorectal, and bone malignancies were predominant.

Key Words: *Hyderabad, Sindh, Cancer registry, Oral cancer, Breast cancer.*

How to cite this article: Pervez S, Khan MR, Ujjan ID, Mumtaz N, Alam E, Qureshi H. Hyderabad (Sindh, Pakistan) Cancer Registry Report of Four Years (2020-2023). *J Coll Physicians Surg Pak* 2025; **35(05)**:622-627.

INTRODUCTION Cancer registries are the backbone of any cancer control

LIAQUAT UNIVERSITY
OF MEDICAL & HEALTH SCIENCES
JAMSHORO

WHO/LUMHS Typhoid Surveillance Programme

Liaquat University of Medical & Health Sciences (LUMHS), in partnership with the **World Health Organization (WHO)**, is implementing the **Typhoid Surveillance Programme** at LUMHS/Liaquat University Hospital, Jamshoro, from **1 January 2025 to 31 December 2026**, contributing to Pakistan's national efforts to monitor typhoid and antimicrobial resistance following the introduction of typhoid conjugate vaccine (TCV) into the routine childhood immunization programme. The programme generates laboratory-confirmed surveillance data on typhoid in Sindh, monitors antimicrobial resistance including **extensively drug-resistant (XDR) Salmonella Typhi**, and contributes evidence for assessing the impact of TCV and informing national and international public-health strategies. Through its laboratory and clinical surveillance capacity, LUMHS contributes to the identification and monitoring of typhoid cases and resistance patterns, supporting evidence-based disease prevention and control. The collaboration demonstrates LUMHS's engagement with a major global health organization and strengthens institutional capacity in infectious disease surveillance, laboratory diagnosis and antimicrobial-resistance monitoring. The initiative directly supports **SDG 3 (Good Health and Well-being)**, particularly Targets 3.3 and 3.d, through communicable disease surveillance, AMR monitoring and strengthening health-system capacity; **SDG 6 (Clean Water and Sanitation)** by generating evidence relevant to the burden and prevention of waterborne disease; and **SDG 17 (Partnerships for the Goals)** through sustained collaboration between LUMHS, WHO and national public-health and immunization efforts.





World Health Organization

Global Procurement and Logistics
Global Service Centre
Block 3510
Jalan Teknokrat 6
63000 Cyberjaya
MALAYSIA

WHO Reference/ Référence OMS

WHO Reference	2026/1650538-0
Purchase Order	203829462
Unit Reference	EPI, Sub-Office, Sindh

COVERING LETTER
LETTRE D'ACCOMPAGNEMENT

Dr. Yusra Shafquat
LIAQUAT UNIVERSITY OF MEDICAL AND HEALTH SCIENCES
HYDERABAD
Diagnostic and Research Laboratory
Liaquat University of Medical and Health Sciences, Civil Hospital, Hyderabad
Hyderabad
Sindh
71000
Pakistan

TECHNICAL SERVICES AGREEMENT (TSA)

Re: This TSA will cover the cost of Typhoid Surveillance for LUMHS from Jan-June 2026

We are enclosing the Technical Services Agreement between the World Health Organization and LIAQUAT UNIVERSITY OF MEDICAL AND HEALTH SCIENCES, HYDERABAD, in the amount of PKR 600,000.00 (Six Hundred Thousand), for conducting the above-mentioned work. We also enclosed two attachment(s) referenced in the Agreement.

Kindly acknowledge your acceptance of this contract by returning the email with a copy of duly signed Purchase Order (all pages).

For any technical or scientific questions related to this Agreement, please contact the responsible technical officer, Ghulam BULEDI LOLAI, buledig@who.int.

On behalf of the World Health Organization, we thank you for your collaboration.

WHO Global Service Centre

Cc: WHO Representative, Pakistan

Concerne: This TSA will cover the cost of Typhoid Surveillance for LUMHS from Jan-June 2026

Veuillez trouver ci-joint l'Accord de Services Techniques entre l'Organisation Mondiale de la Santé et LIAQUAT UNIVERSITY OF MEDICAL AND HEALTH SCIENCES, HYDERABAD, pour un montant de PKR 600,000.00 (Six Hundred Thousand), vous permettant de mener à bien le travail susmentionné. Veuillez également trouver two pièces jointes mentionnées dans l'Accord.

Merci de confirmer votre acceptation de ce contrat en nous retournant le courriel et une copie dûment signee du Bon de Commande (complet)

Pour toutes questions à caractère scientifique ou technique ayant trait à cet Accord, veuillez contacter le responsible technique Ghulam BULEDI LOLAI, buledig@who.int.

Au nom de l'Organisation Mondiale de la Santé, nous vous remercions de votre collaboration.

Centre de Soutien Administratif Mondial de l'OMS

Cc: Représentant de l'OMS, Pakistan

LIAQUAT UNIVERSITY
OF MEDICAL & HEALTH SCIENCES
JAMSHORO

International Collaboration and Participation in the Antimicrobial Chemotherapy Conference 2025

Liaquat University of Medical & Health Sciences (LUMHS) strengthened its international engagement and institutional capacity in antimicrobial resistance (AMR) through participation in the **Antimicrobial Chemotherapy Conference 2025**, held on **4–5 February 2025** and organized by the **Global Antibiotic Research & Development Partnership (GARDP)** and the **British Society for Antimicrobial Chemotherapy (BSAC)**. **Dr. Yusra Shafquat, LUMHS**, participated in this international professional forum, which brought together experts and healthcare professionals working in antimicrobial chemotherapy, antimicrobial stewardship and antimicrobial resistance. Participation provided an opportunity to gain updated knowledge on global developments in antimicrobial treatment and resistance, strengthen professional capacity in rational antibiotic use and antimicrobial stewardship, and establish connections with international organizations working on AMR. Dr. Shafquat was awarded **8 CPD credits**, supporting continuous professional development and the transfer of current knowledge into teaching, clinical practice and research at LUMHS. This activity contributes directly to **SDG 3 (Good Health and Well-being)** by strengthening health-professional capacity to address antimicrobial resistance and health risks; **SDG 4 (Quality Education)** through continuing professional development and enhancement of faculty knowledge; and **SDG 17 (Partnerships for the Goals)** through engagement with international organizations and professional networks. The activity demonstrates LUMHS's commitment to global health priorities, professional capacity building, international collaboration and the dissemination of contemporary knowledge within the university and healthcare community.



Certificate of Participation

AWARDED TO
Dr. Yusra Shafquat

FOR ATTENDING AT THE EVENT
Antimicrobial Chemotherapy Conference 2025, 4 & 5 February, 2025

ORGANISED BY
GARDP and British Society for Antimicrobial Chemotherapy

CPD CREDITS AWARDED
8 Points

SIGNED
Michael Corley
CEO, BSAC

CPD Approved
The Royal College of Pathologists

BSAC GARDP

bsac.org.uk
British Society for Antimicrobial Chemotherapy
Registered Charity 1093118

LIAQUAT UNIVERSITY
OF MEDICAL & HEALTH SCIENCES
JAMSHORO

International Partnership for Antimicrobial Resistance Surveillance: Fleming Fund Country Grant and DAI, Phase II

Liaquat University of Medical & Health Sciences (LUMHS) participated in the **Fleming Fund Country Grant (Pakistan), Phase II, in partnership with DAI**, from 24 April 2024 to 31 December 2025, contributing to collaborative efforts to strengthen antimicrobial resistance (AMR) surveillance and microbiology laboratory capacity. Concrete activities under this partnership included the **refurbishment and upgrading of the Microbiology Laboratory at LUMHS**, the institutional implementation of AMR surveillance-related activities, and the **formal inauguration of the refurbished laboratory on 1 October 2025**. These activities translated international development cooperation into a tangible institutional outcome by strengthening laboratory infrastructure and supporting microbiological diagnostic services, AMR monitoring, clinical practice, teaching and research. The partnership brought together LUMHS's academic, clinical and laboratory expertise with the international development framework provided through the Fleming Fund and DAI, supporting coordinated action on a shared global health priority. The upgraded laboratory provides a strengthened institutional platform for generating microbiological evidence, supporting the identification of antimicrobial resistance patterns and contributing to wider efforts to address drug-resistant infections in Pakistan. This initiative demonstrates LUMHS's contribution to **SDG 17 (Partnerships for the Goals)** through international development cooperation, joint implementation of institutional capacity-strengthening activities, and the translation of partnership support into improved institutional infrastructure. It also contributes to **SDG 3 (Good Health and Well-being)** by strengthening the capacity to address AMR and supports **SDG 4 (Quality Education)** through improved facilities for practical learning and professional development. Supporting evidence includes the grant documentation, laboratory refurbishment records, inauguration photographs and relevant programme reports.



World Health Organization

Global Procurement and Logistics
Global Service Centre
Block 3510
Jalan Teknokrat 6
63000 Cyberjaya
MALAYSIA

WHO Reference/ Référence OMS
WHO Reference 2029/16505538-0
Purchase Order 2033829462
Unit Reference EPI, Sub-Office, Sindh

COVERING LETTER
LETTRE D'ACCOMPAGNEMENT

Dr. Yusra Shafquat
LIAQUAT UNIVERSITY OF MEDICAL AND HEALTH SCIENCES
HYDERABAD
Diagnostic and Research Laboratory
Liaquat University of Medical and Health Sciences, Civil Hospital, Hyderabad
Hyderabad
Sindh
71000
Pakistan

TECHNICAL SERVICES AGREEMENT (TSA)

Re: This TSA will cover the cost of Typhoid Surveillance for LUMHS from Jan-June 2026

We are enclosing the Technical Services Agreement between the World Health Organization and LIAQUAT UNIVERSITY OF MEDICAL AND HEALTH SCIENCES, HYDERABAD, in the amount of PKR 600,000.00 (Six Hundred Thousand), for conducting the above-mentioned work. We also enclosed two attachment(s) referenced in the Agreement.

Kindly acknowledge your acceptance of this contract by returning the email with a copy of duly signed Purchase Order (all pages).

For any technical or scientific questions related to this Agreement, please contact the responsible technical officer, Ghulam BULEDI LOLAI, buledig@who.int.

On behalf of the World Health Organization, we thank you for your collaboration.

WHO Global Service Centre

Cc: WHO Representative, Pakistan

Concerne: This TSA will cover the cost of Typhoid Surveillance for LUMHS from Jan-June 2026

Veuillez trouver ci-joint l'Accord de Services Techniques entre l'Organisation Mondiale de la Santé et LIAQUAT UNIVERSITY OF MEDICAL AND HEALTH SCIENCES, HYDERABAD, pour un montant de PKR 600,000.00 (Six Hundred Thousand), vous permettant de mener à bien le travail susmentionné. Veuillez également trouver two pièces jointes mentionnées dans l'Accord.

Merci de confirmer votre acceptation de ce contrat en nous retournant le courriel et une copie dûment signee du Bon de Commande (complet)

Pour toutes questions à caractère scientifique ou technique ayant trait à cet Accord, veuillez contacter le responsible technique Ghulam BULEDI LOLAI, buledig@who.int.

Au nom de l'Organisation Mondiale de la Santé, nous vous remercions de votre collaboration.

Centre de Soutien Administratif Mondial de l'OMS

Cc: Représentant de l'OMS, Pakistan

.Outcomes and Impact

- Upgraded laboratory infrastructure and facilities.
- Strengthened capacity for AMR surveillance and quality-assured microbiological testing.
- Improved training and research opportunities for students, faculty and technical staff.
- A sustained international partnership contributing to national and global AMR response efforts.
- The strong empirical evidences for policy development.





DAI
Shaping a more livable world.

The Fleming Fund

UKaid
from the British people

Certificate of Appreciation

awarded to

Dr. Yusra Shafqat

Liaquat University of Medical and Health Sciences, Hyderabad/Jamshoro

in recognition of their outstanding contribution and unwavering support towards strengthening **Pakistan's Antimicrobial Resistance (AMR) Surveillance System**

Date: 10th Dec 2025

Dr. Qadeer Ahsan
Team Leader
Fleming Fund Country Grant
DAI Pakistan

Dr. Muhammad Taimoor Kayani
Senior Manager One Health Surveillance
Fleming Fund Country Grant
DAI Pakistan

LIAQUAT UNIVERSITY
OF MEDICAL & HEALTH SCIENCES
JAMSHORO

Collaboration on international level Participation in the Antimicrobial Chemotherapy Conference 2025

A faculty member of Liaquat University of Medical & Health Sciences (LUMHS), Dr. Yusra Shafqat [designation and department to be added], participated in the Antimicrobial Chemotherapy Conference 2025, held on 4–5 February 2025 [venue/mode to be added] and organized by the Global Antibiotic Research & Development Partnership (GARDP) and the British Society for Antimicrobial Chemotherapy (BSAC). The conference brought together professionals working on antimicrobial therapy, stewardship and resistance, a field of major importance because antimicrobial resistance (AMR) is a global health threat that undermines the effective treatment of infections. LUMHS participated to keep abreast of current developments in antimicrobial chemotherapy and resistance, to strengthen institutional capacity in antimicrobial stewardship, and to build linkages with international organizations working on AMR. The participant received 8 CPD credits, approved by the Royal College of Pathologists. The activity contributes to SDG 3 (Good Health and Well-being, Target 3.d), SDG 4 (Quality Education, through faculty professional development) and SDG 17 (Partnerships for the Goals, through engagement with international bodies).

LUMHS Contribution

LUMHS faculty represented LUMHS at the two-day conference and received a Certificate of Participation with 8 CPD credits. The knowledge gained supports LUMHS teaching, clinical practice and research on rational antibiotic use and AMR.

Outcomes

- Faculty participation in an international conference on AMR
- 8 CPD credits earned
- Enhanced institutional awareness of antimicrobial stewardship

LUMHS International Collaboration - Participation in the Global TB Clinical and Educational Summit 2025

Liaquat University of Medical & Health Sciences (LUMHS), participated in the Global TB Clinical and Educational Summit, held from 14 to 17 October 2025 and organized by QIAGEN (CPD Provider No. 1429). Dr Yusra Shafaquat represented LUMHS. The summit brought together clinicians and educators from different countries to share advances in the clinical management and teaching of tuberculosis (TB), which remains one of the leading infectious causes of death worldwide and a major public health challenge in Pakistan, a high-burden country. The participant was awarded 22 CPD hours through the CPD Certification Service, and the learning supports LUMHS teaching, clinical practice and research on TB. The activity contributes to SDG 3 (Good Health and Well-being, Target 3.3), SDG 4 (Quality Education,

through faculty professional development) and SDG 17 (Partnerships for the Goals, through international knowledge exchange).

Objectives of Participation

- To engage with global developments in TB diagnosis, treatment and education
- To strengthen faculty knowledge and capacity in TB management
- To build international professional linkages

LUMHS Contribution

Dr. Yusra Shafqat represented LUMHS at the four-day summit and was awarded 22 CPD hours/points certified through the CPD Certification Service. Learning supports LUMHS teaching, clinical practice and research on TB.

Outcomes

- Faculty participation in a global TB summit
- 22 CPD hours/points earned
- Strengthened international professional linkages
- Enhanced institutional awareness of current TB practice



Certificate of Participation

AWARDED TO
Dr. Yusra Shafquat

FOR ATTENDING AT THE EVENT
Antimicrobial Chemotherapy Conference 2025, 4 & 5 February, 2025

ORGANISED BY
GARDP and British Society for Antimicrobial Chemotherapy

CPD CREDITS AWARDED
8 Points

SIGNED
Michael Corley
CEO, BSAC

CPD Approved
The Royal College of Pathologists

BSAC GARDP

bsac.org.uk
British Society for Antimicrobial Chemotherapy
Registered Charity 1093118



CERTIFICATE
OF
CONTINUING PROFESSIONAL DEVELOPMENT

The CPD Certification Service certifies that

Yusra Shafquat

the above named has participated in the following CPD activity

Global TB Clinical and Educational Summit - Oct 14-17,2025

CPD Provider Organisation
QIAGEN
CPD Provider No: 1429

An initiative to increase standards of CPD provision to professionals in relevant market sectors

CPD CERTIFIED The CPD Certification Service

Date of CPD Activity: 17/10/2025
No. CPD Hours / Points: 22



CERTIFICATE
OF
CONTINUING PROFESSIONAL DEVELOPMENT

The CPD Certification Service certifies that

Yusra Shafquat

the above named has participated in the following CPD activity

QIAGEN World TB Day 2025

CPD Provider Organisation
QIAGEN
CPD Provider No: 1429

An initiative to increase standards of CPD provision to professionals in relevant market sectors

CPD CERTIFIED The CPD Certification Service

Date of CPD Activity: 24/03/2025
No. CPD Hours / Points: 4

LIAQUAT UNIVERSITY
OF MEDICAL & HEALTH SCIENCES
JAMSHORO